TICKERNERD
Menu
LQDALQDAHealthcare · Drug Manufacturers - Specialty & Generic

LQDA Stock Forecast: Liquidia Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$67
−1.64% on the day

The 8 Wall Street analysts covering Liquidia Corp. hold a median 12-month price target of $109 — +63.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.0B
Ticker Nerd rank
78 / 100
Median analyst target
$109
Analysts covering
8
Revenue$171.7M+1842.7% y/y
Operating income$85.5M
Net income$74.7M
Free cash flow$68.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.8%
1M
−24.2%
YTD
+93.5%
1Y
+147.2%
From 52W high
−26.7%
From 52W low
+206.1%
$22
$91
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LQDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Liquidia Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
78 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
100
Growth
97
Value
96
Momentum
96
Volatility
71
Revisions
49
Accruals
27
Size
21
Issuance
17

Quality (100): The business earns solid, repeatable profits on what it owns.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LQDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LQDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26LQDAHigh $130Median $109Low $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
6 Buy2 Hold0 Sell
Low $90Median $109High $130

The green dot is the last close — the median target sits +63.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 18 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026B of A SecuritiesMaintainsNeutral$79 → $92
13 Aug 2026Wells FargoMaintainsOverweight$62 → $108
12 Aug 2026BTIGMaintainsBuy$109 → $111
12 Aug 2026LifeSci CapitalDowngradeMarket Perform$90
12 Aug 2026NeedhamMaintainsBuy$70 → $110
23 July 2026HC Wainwright & Co.MaintainsBuy$75 → $130
29 June 2026B of A SecuritiesDowngradeNeutral$64 → $79
22 June 2026BTIGMaintainsBuy$59 → $109
5 June 2026HC Wainwright & Co.MaintainsBuy$67 → $75
12 May 2026HC Wainwright & Co.MaintainsBuy$55 → $67
12 May 2026Wells FargoMaintainsOverweight$51 → $62
11 May 2026BTIGMaintainsBuy$50 → $59
11 May 2026NeedhamMaintainsBuy$54 → $70
23 Mar 2026Wells FargoMaintainsOverweight$44 → $51
12 Mar 2026OppenheimerMaintainsUnderperform$16 → $19
6 Mar 2026HC Wainwright & Co.MaintainsBuy$50 → $55
6 Mar 2026Wells FargoMaintainsOverweight$31 → $44
5 Mar 2026BTIGMaintainsBuy$49 → $50
5 Mar 2026NeedhamMaintainsBuy$52 → $54
25 Feb 2026NeedhamReiteratesBuy$52

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LQDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LQDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Liquidia Corp. returned +147.2% against +17.5% for the S&P 500, dividends included.

LQDA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Oct 25Jan 26Apr 26Jul 26LQDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LQDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−7.5%
Analysts raising
0
Analysts cutting
5
Fundamentals

Liquidia Corp. (LQDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
47.7×

Cheaper than 15% of US stocks

Price / sales
13.2×

Cheaper than 12% of US stocks

Price / book
30.5×

Cheaper than 3% of US stocks

EV / EBITDA
34.6×

Cheaper than 7% of US stocks

Growth & margins
Revenue growth (YoY)
1842.7%

Higher than 99% of US stocks

Earnings growth (YoY)
1842.7%

Higher than 98% of US stocks

Gross margin
93.3%

Higher than 97% of US stocks

Operating margin
49.8%

Higher than 96% of US stocks

Net margin
30.7%

Higher than 90% of US stocks

Returns & dividend
Return on equity
131.8%

Higher than 97% of US stocks

Return on assets
27.0%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Liquidia Corp. (LQDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Liquidia Corp. has a market value of $6.0B and an enterprise value of $5.9B.

  • Revenue in the twelve months to 30 June 2026: $450.9M. The latest quarter grew 1842.7% year on year.

  • Net income over the same four quarters: $138.6M, a 30.7% net margin.

  • Diluted earnings per share, trailing twelve months: $1.37.

  • Free cash flow in the twelve months to 30 June 2026: $147.7M.

  • Shares outstanding: 89.1M.

  • Trailing P/E: 47.7×; forward P/E: 11.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Liquidia Corp. employs 216 people — $2.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

LQDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
LQDALiquidia Corp.$6.0B
78
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98
HIMSHims & Hers Health, Inc.$6.4B
17
LNTHLantheus Holdings, Inc.$6.5B
88
AMRXAmneal Pharmaceuticals, Inc.$5.3B
83
ALKSAlkermes Plc$7.6B
62
INDVIndivior Pharmaceuticals, Inc.$4.1B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Liquidia Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LQDA news & analysis

LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?

Zacks Investment Research · 11 Sept 2026negative

Liquidia Corp. stock fell 13.9% over the past month. Although its product Yutrepia is gaining traction, patent litigation, competition, rising costs, and heavy product dependence cloud the company's outlook, according to Zacks Investment Research.

Why it matters — LQDA watchers would care because the report highlights the mix of Yutrepia's growth against the legal, competitive, and cost risks that weigh on the company's prospects.

Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?

Zacks Investment Research · 10 Sept 2026positive

Liquidia's lead drug Yutrepia received FDA Fast Track designation for the treatment of systemic sclerosis-related Raynaud's phenomenon. This designation opens up a potential new growth avenue and possible label expansion for Yutrepia.

Why it matters — A LQDA watcher would care because the Fast Track designation could broaden Yutrepia's approved uses and expand the drug's overall commercial potential.

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

GlobeNewsWire · 3 Sept 2026positive

The FDA granted Fast Track designation to Liquidia's YUTREPIA (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). No therapy is currently approved in the U.S. for SSc-RP, and Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026.

Why it matters — The Fast Track designation signals regulatory recognition of the significant unmet need in SSc-RP and supports the advancement of Liquidia's YUTREPIA program into a new indication.

Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress

GlobeNewsWire · 2 Sept 2026neutral

Liquidia Corporation announced it will present two posters at the European Respiratory Society (ERS) 2026 Congress, held September 5-9, 2026, in Barcelona, Spain. The announcement covers the company's upcoming scientific presentations at the conference.

Why it matters — LQDA watchers would care because the ERS Congress presentations give the company a platform to showcase its respiratory and vascular disease research to the wider medical community.

Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

GlobeNewsWire · 1 Sept 2026neutral

Liquidia Corporation announced that its Chief Operating Officer and Chief Financial Officer, Michael Kaseta, and Chief Business Officer, Jason Adair, will provide an update on the company's business during a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026.

Why it matters — The conference participation gives LQDA watchers an opportunity to hear company leadership discuss the state of the business in a public forum.

FAQ

Frequently asked questions about LQDA stock

What is the LQDA stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Liquidia Corp. have a median 12-month price target of $109, with estimates ranging from $90 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LQDA stock a buy right now?

Of the 8 analysts covering Liquidia Corp., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Liquidia Corp. 78 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LQDA?

As at 12 Sept 2026, Liquidia Corp. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).

Will LQDA stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +63.3% from the last close, and Ticker Nerd's factor model ranks Liquidia Corp. 78 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LQDA stock forecast for 2030?

No analyst covering Liquidia Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LQDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $130 over the next 12 months.

How has LQDA stock performed over the past year?

Liquidia Corp. returned +147.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Liquidia Corp. do?

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats.

What is the latest news on LQDA?

The most recent item we track (Zacks Investment Research, 11 Sept 2026): "LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?". Liquidia Corp. stock fell 13.9% over the past month. Although its product Yutrepia is gaining traction, patent litigation, competition, rising costs, and heavy product dependence cloud the company's outlook, according to Zacks Investment Research.

Company

About Liquidia Corp.

Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats. Liquidia’s work spans product development, manufacturing, and commercialization, giving it a role across the full lifecycle of specialty respiratory medicines. Its marketed and investigational programs are aimed at patients with challenging respiratory and vascular conditions, positioning the company within the rare-disease and specialty pharmaceutical markets. Liquidia Corporation is headquartered in Morrisville, North Carolina.

CEO Dr. Roger A. Jeffs Ph.D. · 216 employees · United States · https://www.liquidia.com